BRIEF-Shanghai Henlius Biotech Announces License Agreement With Getz Pharma For Rights Of Handayuan
February 23, 2022 by Reuters
Share this article:
Feb 23 (Reuters) – Shanghai Henlius Biotech Inc 2696.HK:
-
ANNOUNCES LICENSE AGREEMENT WITH GETZ PHARMA FOR RIGHTS OF HANDAYUAN
-
TO GRANT LICENSE TO GETZ PHARMA TO COMMERCIALISE ADALIMUMAB INJECTION IN PAKISTAN, PHILIPPINES, AMONG OTHER COUNTRIES
Further company coverage: 2696.HK
This article originally appeared on reuters.com